Influence of the SCN1A IVS5N + 5 G>A Polymorphism on Therapy with Carbamazepine for Epilepsy

Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia. 2009; 50(1): 1-23.10.1111/j.1528-1167.2008.01716.xSearch in Google Scholar

Yu FH, Catterall WA. Overview of the voltage-gated sodium channel family. Genome Biol. 2003; 4(3): 207.10.1186/gb-2003-4-3-207Search in Google Scholar

George AL Jr. Inherited disorders of voltage-gated sodium channels. J Clin Invest. 2005; 115(8): 1990-1999.10.1172/JCI25505Search in Google Scholar

Plummer NW, Meisler MH. Evolution and diversity of mammalian sodium channel genes. Genomics. 1999; 57(2): 323-331.10.1006/geno.1998.5735Search in Google Scholar

Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, Thom M, Sen A, Shorvon SD, Sander JW, Wood NW, Goldstein DB. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci USA. 2005; 102(15): 5507-5512.10.1073/pnas.0407346102Search in Google Scholar

Tate SK, Singh R, Hung CC, Tai JJ, Depondt C, Cavalleri GL, Sisodiya SM, Goldstein DB, Liou HH. A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet Genomics. 2006; 16(10): 721-726.10.1097/01.fpc.0000230114.41828.73Search in Google Scholar

Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M, Nakagawa K. Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Br J Clin Pharmacol. 2008; 66(2): 304-307.10.1111/j.1365-2125.2008.03203.xSearch in Google Scholar

Zimprich F, Stogmann E, Bonelli S, Baumgartner C, Mueller JC, Meitinger, T, Zimprich A, Strom TM. A functional polymorphism in the SCN1A gene is not associated with carbamazepine dosages in Austrian patients with epilepsy. Epilepsia. 2008; 49(6): 1108-1109.10.1111/j.1528-1167.2008.01549_4.xSearch in Google Scholar

Heinzen EL, Yoon W, Tate SK, Sen A, Wood NW, Sisodiya SM, Goldstein DB. Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. Am J Hum Genet. 2007; 80(5): 876-883.10.1086/516650Search in Google Scholar

Thompson CH, Kahlig KM, George AL Jr. SCN1A splice variants exhibit divergent sensitivity to commonly used antiepileptic drugs. Epilepsia. 2011; 52(5): 1000-1009.10.1111/j.1528-1167.2011.03040.xSearch in Google Scholar

Sánchez MB, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizán EM, Nicolás JM, Adín J, Armijo JA. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. Seisure. 2010; 19(2): 93-101.10.1016/j.seizure.2009.12.004Search in Google Scholar

Manna I, Gambardella A, Bianchi A, Striano P, Tozzi R, Aguglia U, Beccaria F, Benna P, Campostrini R, Canevini MP, Condino F, Durisotti C, Elia M, Giallonardo AT, Iudice A, Labate A, La Neve A, Michelucci R, Muscas GC, Paravidino R, Zaccara G, Zucca C, Zara F, Perucca E. A functional polymorphism in the SCN1A gene does not infl uence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia. 2011; 52(5): 1528-1167.10.1111/j.1528-1167.2011.03097.xSearch in Google Scholar

Depondt C. The potential of pharmacogenetics in the treatment of epilepsy. Eur J Paediatr Neurol. 2006; 10(2): 57-65.10.1016/j.ejpn.2005.11.009Search in Google Scholar